Antibacterial, antifungal, and hemolytic activity data of Series 1 (1a-16a), Series 2 (1b-16b), series 3 (1c-24c), Series 4 (1d-24d), and Series 5 (1e-11e), cyclic peptides and parent cyclic peptides (p1, p2, p3, p4, and p5) of each series. (A) a The minimum inhibitory concentration (MIC) heatmap of cyclic peptides against Gram-positive and Gram-negative bacterial strains and fungal strains. MIC is the lowest concentration of the peptides that inhibited bacterial growth. b Non-resistant (wild type) bacterial strain. c Methicillin-resistant Staphylococcus aureus. d Vancomycin-resistant enterococci strain. e Multi-drug resistant (Penicillin, Tetracycline, and Erythromycin) bacterial strain. f NDM-1, g Carbapenem, h Ciprofloxacin, i Imipenem resistant bacterial strains. j Multi-drug resistant clinical isolate of A. fumigatus. k Non-resistant (wild type) candida strains. The data represents the results of the experiments performed in triplicate.(B) The therapeutic index of each cyclic peptide is calculated by dividing HC50 with the MIC (observed against a representative Gram-positive strain S. aureus (ATCC 29213)) of each peptide. (C) Hemolytic activity of the peptides was determined using human red blood cells (hRBC) as HC50 values. The black color bar in each graph represents the HC50 and therapeutic index of parent peptides (p1, p2, p3, p4, and p5). Green color bars represent the peptides with high therapeutic index within the respective series. The data represents the experiment performed in triplicate.